Related Experiment Videos

Mupirocin resistance in methicillin-resistant Staphylococcus aureus from a veterans hospital

M H Naguib1, M T Naguib, D J Flournoy

  • 1Laboratory Service, Veterans Affairs Medical Center, Oklahoma City, OK 73104.

Chemotherapy
|November 1, 1993
PubMed

Insights

Mupirocin resistance in methicillin-resistant Staphylococcus aureus (MRSA) is low but increasing. Nine of 679 MRSA isolates were resistant, with a concerning rise in cases during 1992, signaling a potential future threat.

Area of Science:

  • Clinical microbiology
  • Infectious diseases
  • Antimicrobial resistance

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) is a significant healthcare-associated pathogen.
  • Mupirocin is a crucial topical antibiotic for treating MRSA infections.
  • The emergence of mupirocin resistance in MRSA is a growing public health concern.

Purpose of the Study:

  • To determine the frequency of mupirocin resistance among clinical MRSA isolates.
  • To analyze trends in mupirocin resistance over time.

Main Methods:

  • Retrospective analysis of 679 MRSA isolates collected between 1986 and 1992.
  • Disk agar diffusion screening using a 5 µg mupirocin disk.
  • Agar dilution method to determine Minimal Inhibitory Concentrations (MICs) for suspect isolates.

Main Results:

  • Twenty-six out of 679 MRSA isolates (3.8%) showed zones of inhibition < 18 mm, suggesting potential resistance.
  • Nine isolates (1.3% of total) were confirmed resistant to mupirocin, with MICs ranging from 6.25 to >1,000 µg/ml.
  • A notable increase in resistant isolates was observed in 1992, with 5 out of 9 resistant strains identified that year.

Conclusions:

  • The overall incidence of mupirocin resistance in this MRSA cohort was low.
  • The increasing trend of mupirocin resistance, particularly in recent years (1992), warrants close monitoring.
  • This rise may indicate a developing threat that could compromise future MRSA treatment strategies.

Related Concept Videos